JPRN-jRCT1041210066进行中（未招募）未知
Effect of Sacubitril/valsartan on Left Ventricular Extracellular Volume in Heart Failure With Reduced Ejection Fraction
Dohi Kaoru0 个研究点目标入组 66 人开始时间: 2021年9月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) patients with HF symptoms (NYHA class I-III)
- •(2) patients with echo or MRI LVEF<50% measured within last 3 months
- •(3) patients treated with up-titration of heart failure medications for at least 4 weeks
- •(4) patients with BNP level > or =18.4pg/ml or NT-pro BNP level > or =100 pg/ml within last 3 months
- •(5) patients aged > or = 20 years
- •(6) Japanese
- •(7) patients who are able to give informed consent
排除标准
- •(1) patients with symptomatic hypotension and/or systolic blood pressure <90 mmHg
- •(2) patients with eGFR <30 mL/min/1.73m2
- •(3) patients with acute coronary syndrome, stroke, cardiovascular surgery, carotid artery surgery, other major cardiac surgery, or percutaneous coronary intervention within last 3 months
- •(4) patients with hospitalization due to heart failure within last 6 months
- •(5) patients with persistent/permanent atrial fibrillation
- •(6) patients with implantable cardiac devices
- •(7) patients with diagnosed or suspected cardiac amyloidosis
- •(8) patients with severe valvular heart disease except for severe functional mitral regurgitation
- •(9) patients with serum potassium >5.2 mmol/L
- •(10) patients with histories of angioedema
- •(11) patients with hypersensitivity or allergy to heart failure medications
- •(12) patients with unstable angina
- •(13) patients with liver dysfunction (AST or ALT 100 IU/L or more)
- •(14) patients with pregnancy or suspected pregnancy or patients with breast-feeding
- •(15) patients enrolled in a separate clinical trial or study within the past 3 months
- •(16) patients who are not eligible to participate in this study
研究者
相似试验
已完成
不适用
Effect of sacubitril-valsartan on cardiac function in hemodialysis patientsheart failureJPRN-UMIN000044773Daimon Clinic for Internal Medicine, Nephrology and Dialysis7
招募中
2 期
Investigating the effect of valsartan sacubitril on left ventricular functioIRCT20240117060713N1Ahvaz University of Medical Sciences92
进行中（未招募）
1 期
Studying the effect of medication (sacubitril/valsartan) on heart muscle damage after heart attacksAsymptomatic (New York Heart Association =2) left ventricular systolic dysfunction (defined as ejection fraction =40% measured by Simpson's biplane using transthoracic echocardiography) at least 3 months post myocardial infarctionMedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.1Level: LLTClassification code 10064079Term: Heart failure NYHA class ISystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10069501Term: Left ventricular systolic dysfunctionSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10000891Term: Acute myocardial infarctionSystem Organ Class: 10007541 - Cardiac disordersEUCTR2017-003460-13-GBHS Greater Glasgow and Clyde100
已完成
不适用
Effect of sacubitril/valsartan versus valsartan on blood pressure in hypertensive patients with chronic heart failure and chronic kidney disease, a parallel-group randomized controlled trialHypertension with chronic heart failure and chronic kidney diseaseJPRN-UMIN000043657Yokohama City University Medical Center62
尚未招募
不适用
To study the effect of the drug Sacubutril-Valsartan on diastolic function in heart failure patientsCTRI/2020/04/024445Kasturba Medical College Manipal Academy of Higher Education Manipal